2022
Epidemiology and outcomes of surgical site infections among pediatric liver transplant recipients
Banach DB, Lopez‐Verdugo F, Sanchez‐Garcia J, Tran A, Gomez‐Llerena A, Munoz‐Abraham A, Bertacco A, Valentino PL, Yoo P, Dembry L, Mulligan DC, Ekong UD, Emre SH, Rodriguez‐Davalos M. Epidemiology and outcomes of surgical site infections among pediatric liver transplant recipients. Transplant Infectious Disease 2022, 24: e13941. PMID: 35989545, DOI: 10.1111/tid.13941.Peer-Reviewed Original ResearchConceptsSurgical site infectionLiver transplant recipientsLiver transplantationBiliary complicationsGraft recipientsTransplant recipientsSite infectionRisk factorsOutcomes of SSIPediatric liver transplant recipientsLong-term graftPediatric liver transplantationRetrospective descriptive analysisPrimary endpointHospital daysPatient agePediatric populationPatient survivalSignificant causeComplicationsPatientsRecipientsOutcomesInfectionIncidence
2020
Human Small Intestine Transplantation: Segmental Susceptibility to Ischemia Using Different Preservation Solutions and Conditions
Lysyy T, Finotti M, Maina RM, Morotti R, Munoz-Abraham AS, Bertacco A, Ibarra C, Barahona M, Agarwal R, D'Amico F, Rodriguez-Davalos MI, Mulligan D, Geibel J. Human Small Intestine Transplantation: Segmental Susceptibility to Ischemia Using Different Preservation Solutions and Conditions. Transplantation Proceedings 2020, 52: 2934-2940. PMID: 32768284, DOI: 10.1016/j.transproceed.2020.06.031.Peer-Reviewed Original ResearchConceptsContinuous perfusion preservationIntestinal graftIschemic damagePerfusion preservationAppropriate graft selectionCold static storageSmall intestinal graftsSmall intestine graftDifferent preservation solutionsBlinded histological evaluationCross clampIntestine graftsPostoperative complicationsDifferent time pointsIschemic injuryDeceased donorsPatient survivalGraft selectionRinger's lactateHistological evaluationBack tableVascular perfusionLuminal flushAbdominal organsSmall intestine
2018
Robotic Assisted Kidney Transplant, Reserved for the Deserved
Batra R, Mulligan D, Kulkarni S, Bhati C. Robotic Assisted Kidney Transplant, Reserved for the Deserved. Journal Of Clinical And Experimental Transplantation 2018, 3: 1-3. DOI: 10.4172/2475-7640.1000e104.Peer-Reviewed Original ResearchRobotic kidney transplantKidney transplantTransplant surgeryLower wound complicationsKidney transplant surgeryGeneral surgical proceduresOpen conventional surgeryMinimal invasive surgeryObese patientsWound complicationsPatient survivalPoor outcomeCertain patientsConventional surgerySurgical proceduresHigh incidenceObesity ratesTransplantSurgeryInvasive surgeryComplicationsObesityPatientsErgonomic advantagesGraft
2016
The impact of broader regional sharing of livers: 2‐year results of “Share 35”
Edwards EB, Harper AM, Hirose R, Mulligan DC. The impact of broader regional sharing of livers: 2‐year results of “Share 35”. Liver Transplantation 2016, 22: 399-409. PMID: 26890858, DOI: 10.1002/lt.24418.Peer-Reviewed Original ResearchConceptsWaiting list mortalityLiver transplantLiver diseaseEnd-stage liver disease candidatesEnd-stage liver diseasePosttransplant survival outcomesChronic liver diseaseCold ischemia timeShare 35 policyRegional sharingBroader regional sharingPost-policy periodPosttransplant graftUrgent groupIschemia timePatient survivalSurvival outcomesMedian MELDMortality rateSickest candidatesOrgan procurementTransplantation NetworkTransplantAge groupsUrgent patients
2011
A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C
Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG. A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transplantation 2011, 17: 1394-1403. PMID: 21850690, DOI: 10.1002/lt.22417.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedAntiviral AgentsBiopsyChi-Square DistributionDaclizumabDrug Therapy, CombinationFemaleGraft RejectionHepacivirusHepatitis C, ChronicHumansImmunoglobulin GImmunosuppressive AgentsKaplan-Meier EstimateLiver FailureLiver TransplantationMaleMiddle AgedMycophenolic AcidProportional Hazards ModelsProspective StudiesRecurrenceRisk AssessmentRisk FactorsRNA, ViralSurvival RateTacrolimusTime FactorsTreatment OutcomeUnited StatesConceptsAcute cellular rejectionSteroid-free immunosuppressionLiver transplant recipientsHCV recurrenceMycophenolate mofetilTransplant recipientsHCV RNA-positive subjectsHepatitis C virus infectionSevere HCV recurrenceSteroid-free groupC virus infectionChronic hepatitis CGraft survival ratesProportion of patientsLiver biopsy samplesCellular rejectionChronic HCVStandard immunosuppressionSteroid sparingHepatitis CLess diabetesMulticenter trialMulticenter studyPatient survivalArm 1
2010
Outcomes After Simultaneous Pancreas and Kidney Transplantation and the Discriminative Ability of the C-peptide Measurement Pretransplant Among Type 1 and Type 2 Diabetes Mellitus
Chakkera HA, Bodner JK, Heilman RL, Mulligan DC, Moss AA, Mekeel KL, Mazur MJ, Hamawi K, Ray RM, Beck GL, Reddy KS. Outcomes After Simultaneous Pancreas and Kidney Transplantation and the Discriminative Ability of the C-peptide Measurement Pretransplant Among Type 1 and Type 2 Diabetes Mellitus. Transplantation Proceedings 2010, 42: 2650-2652. PMID: 20832562, PMCID: PMC3060052, DOI: 10.1016/j.transproceed.2010.04.065.Peer-Reviewed Original ResearchMeSH KeywordsAdultC-PeptideCreatinineDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic NephropathiesDiabetic RetinopathyFemaleFollow-Up StudiesGlycated HemoglobinGraft RejectionHumansKidney Failure, ChronicKidney TransplantationMaleMiddle AgedPancreas TransplantationRetrospective StudiesSurvival AnalysisTissue DonorsConceptsEnd-stage renal diseaseType of diabetesC-peptideSimultaneous pancreasKidney transplantationPatient survivalGlutamic acid decarboxylase antibodiesType 2 diabetes mellitusDetectable C-peptideMean creatinine clearanceRenal Disease equationModification of DietBody mass indexC-peptide measurementsRegression survival analysisGlycosylate hemoglobinDiabetic ketoacidosisESRD patientsPancreas transplantationT2DM patientsCreatinine clearanceDecarboxylase antibodiesOral hypoglycemicsRenal replacementDiabetes mellitusEarly Graft Function After Laparoscopically Procured Living Donor Kidney Transplantation
Tyson M, Castle E, Andrews P, Heilman R, Mekeel K, Moss A, Mulligan D, Reddy K. Early Graft Function After Laparoscopically Procured Living Donor Kidney Transplantation. Journal Of Urology 2010, 184: 1434-1439. PMID: 20727548, DOI: 10.1016/j.juro.2010.06.013.Peer-Reviewed Original ResearchConceptsPoor early graft functionEarly graft functionLiving-donor kidney transplantationGraft functionDonor kidney transplantationAcute rejectionKidney transplantationMultivariate logistic regression modelGraft function groupDelayed graft functionDonor kidney transplantsInstitutional review boardLogistic regression modelsAllograft survivalGraft nephrectomyVascular complicationsKidney transplantPerioperative parametersIndependent predictorsTransplantation databaseClinical outcomesPatient survivalBlack ethnicityMale genderDonor age
2009
Natural history of post–liver transplantation hepatitis C: A review of factors that may influence its course
Gallegos‐Orozco J, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, de Petris G, Williams JW, Rakela J, Vargas HE. Natural history of post–liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transplantation 2009, 15: 1872-1881. PMID: 19938138, DOI: 10.1002/lt.21954.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultBiopsyDisease ProgressionFemaleGraft RejectionHepatitis CHumansKaplan-Meier EstimateLiver CirrhosisLiver FailureLiver TransplantationLiving DonorsMaleMiddle AgedProportional Hazards ModelsRecurrenceRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTreatment OutcomeConceptsEnd-stage liver diseaseHCV-positive recipientsLiver transplantHepatocellular carcinomaHCV recurrenceAcute rejectionPatient survivalBiopsy-proven acute rejectionMedian age 53 yearsHistory of HCCAggressive HCV recurrenceEarly acute rejectionProtocol liver biopsiesSignificant HCV recurrenceAdult liver transplantsAdvanced donor ageAge 53 yearsAge 39 yearsDay of transplantationLong-term survivalElectronic medical recordsAvoidance of rejectionEvaluable populationRapid fibrosersHepatitis C
2008
Living donor liver transplantation in polycystic liver disease
Mekeel KL, Moss AA, Reddy KS, Douglas DD, Vargas HE, Carey EJ, Byrne TJ, Harrison ME, Rakela J, Mulligan DC. Living donor liver transplantation in polycystic liver disease. Liver Transplantation 2008, 14: 680-683. PMID: 18433036, DOI: 10.1002/lt.21423.Peer-Reviewed Original ResearchConceptsPolycystic liver diseaseDonor liver transplantationLiver transplantationLiver diseaseLiver functionEnd-Stage Liver Disease (MELD) systemDeceased donor liver transplantDonor liver transplantLiver transplantCaval resectionPoor qualityMassive hepatomegalyPatient survivalLiving donationPatientsHepatomegalyTransplantationHepatectomyDiseaseIdeal optionLDLTResectionComplicationsTransplantGraft
2006
Reduced Priority MELD Score for Hepatocellular Carcinoma Does Not Adversely Impact Candidate Survival Awaiting Liver Transplantation
Sharma P, Harper AM, Hernandez JL, Heffron T, Mulligan DC, Wiesner RH, Balan V. Reduced Priority MELD Score for Hepatocellular Carcinoma Does Not Adversely Impact Candidate Survival Awaiting Liver Transplantation. American Journal Of Transplantation 2006, 6: 1957-1962. PMID: 16771808, DOI: 10.1111/j.1600-6143.2006.01411.x.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationHepatocellular carcinomaHCC candidatesCandidate survivalLiver transplantationMELD scoreStage T1Waiting listEnd-stage liver diseaseDonor liver transplantationT2 hepatocellular carcinomaOrgan allocation policyUNOS databaseLiver transplantLiver diseasePatient survivalUnited NetworkHCC patientsIncidence rateOrgan SharingSurvivalTransplantationCarcinomaDropout rateTime period
2004
Hepatitis C Virus Infection with Hepatocellular Carcinoma: Not A Controversial Indication for Liver Transplantation
Rodriguez-Luna H, Balan V, Sharma P, Byrne T, Mulligan D, Rakela J, Vargas HE. Hepatitis C Virus Infection with Hepatocellular Carcinoma: Not A Controversial Indication for Liver Transplantation. Transplantation 2004, 78: 580-583. PMID: 15446318, DOI: 10.1097/01.tp.0000129797.30999.69.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionC virus infectionHepatocellular carcinomaHCV/Liver transplantationVirus infectionChronic hepatitis C virus (HCV) infectionSurvival rateChronic HCV infectionOrthotopic liver transplantationOutcomes of patientsOrgan Sharing dataHCC recurrence rateOverall survival rateLower survival rateHCV groupLT patientsHCV infectionHCC recurrencePatient survivalRecurrence rateUnited NetworkMean agePotential contraindicationsHCC group